Uy Ear's Stock Ratings

Mizuho Analyst

Uy Ear is an analyst at Mizuho. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/31/2024

Overall Average Return

1.45%

Smart Score

48.5%

Overall Average Return Percentile

40th

Number of Ratings

59
Buy NowGet Alert
05/24/2024RNACBuy Now
Cartesian Therapeutics
$30.1232.8% → $40Initiates → BuyGet Alert
05/17/2024SRPTBuy Now
Sarepta Therapeutics
$130.1637.52%$145 → $179MaintainsBuyGet Alert
05/15/2024ARQTBuy Now
Arcutis Biotherapeutics
$8.36115.31%$17 → $18MaintainsBuyGet Alert
05/09/2024ACADBuy Now
ACADIA Pharmaceuticals
$15.1039.07%$25 → $21MaintainsNeutralGet Alert
05/08/2024QUREBuy Now
uniQure
$4.9521.21%$7 → $6MaintainsNeutralGet Alert
04/26/2024SAGEBuy Now
Sage Therapeutics
$11.1162.02%$20 → $18MaintainsNeutralGet Alert
03/12/2024ACADBuy Now
ACADIA Pharmaceuticals
$15.1065.56%$39 → $25DowngradeBuy → NeutralGet Alert
03/08/2024EOLSBuy Now
Evolus
$12.9377.88%$20 → $23MaintainsBuyGet Alert
03/04/2024QUREBuy Now
uniQure
$4.9541.41%$10 → $7MaintainsNeutralGet Alert
02/28/2024ARQTBuy Now
Arcutis Biotherapeutics
$8.36103.35%$16 → $17ReiteratesBuy → BuyGet Alert
02/28/2024ACADBuy Now
ACADIA Pharmaceuticals
$15.10158.28%$40 → $39MaintainsBuyGet Alert
02/23/2024ARQTBuy Now
Arcutis Biotherapeutics
$8.3691.39%$8 → $16ReiteratesBuy → BuyGet Alert
02/14/2024SRPTBuy Now
Sarepta Therapeutics
$130.1611.4%$130 → $145MaintainsBuyGet Alert
02/08/2024NBIXBuy Now
Neurocrine Biosciences
$135.413.39%$116 → $140MaintainsNeutralGet Alert
01/03/2024ARQTBuy Now
Arcutis Biotherapeutics
$8.36-4.31%$4 → $8UpgradeNeutral → BuyGet Alert
01/02/2024ARQTBuy Now
Arcutis Biotherapeutics
$8.36-4.31%$4 → $8UpgradeNeutral → BuyGet Alert
12/29/2023ACADBuy Now
ACADIA Pharmaceuticals
$15.10164.9%$35 → $40MaintainsBuyGet Alert
12/19/2023QUREBuy Now
uniQure
$4.95102.02% → $10DowngradeBuy → NeutralGet Alert
12/18/2023AVROBuy Now
Avrobio
$1.4537.93%$5 → $2DowngradeBuy → NeutralGet Alert
11/22/2023RVNCBuy Now
Revance Therapeutics
$2.80471.43%$35 → $16MaintainsBuyGet Alert
11/10/2023NBIXBuy Now
Neurocrine Biosciences
$135.41-15.81%$116 → $114MaintainsNeutralGet Alert
11/06/2023ACADBuy Now
ACADIA Pharmaceuticals
$15.10131.79%$20 → $35UpgradeNeutral → BuyGet Alert
11/03/2023NBIXBuy Now
Neurocrine Biosciences
$135.41-14.33%—MaintainsNeutralGet Alert
10/27/2023ARQTBuy Now
Arcutis Biotherapeutics
$8.36-52.15%$57 → $4DowngradeBuy → NeutralGet Alert
10/26/2023ALKSBuy Now
Alkermes
$23.2550.54%$37 → $35MaintainsBuyGet Alert
09/26/2023SRPTBuy Now
Sarepta Therapeutics
$130.1622.93% → $160ReiteratesBuy → BuyGet Alert
09/25/2023ARQTBuy Now
Arcutis Biotherapeutics
$8.36581.82% → $57ReiteratesBuy → BuyGet Alert
09/13/2023NBIXBuy Now
Neurocrine Biosciences
$135.41-16.55% → $113ReiteratesNeutral → NeutralGet Alert
08/18/2023SELBBuy Now
Selecta Biosciences
——$4 → $3MaintainsBuyGet Alert
08/02/2023NBIXBuy Now
Neurocrine Biosciences
$135.41-17.29%$111 → $112MaintainsNeutralGet Alert

Recent Analyst Stock Rating News

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
12 Analysts Have This To Say About Sarepta Therapeutics
What Analysts Are Saying About Sarepta Therapeutics Stock
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
Where Neurocrine Biosciences Stands With Analysts
From AI Hype To A New Market High: More Evidence That AI Isn't Just Hype--It's For Real
From AI Hype To A New Market High Yesterday, The Market Ear wrote about how AI adoption could lead to a new market high: 
Expert Ratings For ACADIA Pharmaceuticals
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free